Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.47 |
| ▸ | AHR | P35869 | 4/20 | 0.46 |
| ▸ | CMA1 | P23946 | 1/20 | 0.46 |
| ▸ | F7 | P08709 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | F3 | P13726 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2272066 | 0.93 | CSNK2A1 (0.55) | CSNK2A1GPR84AHRCMA1F7 | |
| SCHEMBL28777719 | 0.84 | GPR84 (0.54) | CSNK2A1GPR84AHRCMA1F7 | |
| SCHEMBL8957459 | 0.81 | CSNK2A1 (0.50) | CSNK2A1GPR84AHRCMA1F7 | |
| SCHEMBL17703916 | 0.79 | GPR84 (0.64) | CSNK2A1GPR84AHRCMA1F7 | |
| SCHEMBL3497908 | 0.78 | GPR84 (0.47) | CSNK2A1GPR84AHRCMA1F7 | |
| SCHEMBL850198 | 0.78 | CSNK2A1 (0.55) | CSNK2A1GPR84AHRCMA1F7 | |
| SCHEMBL3334627 | 0.78 | GPR84 (0.47) | CSNK2A1GPR84AHRCMA1F7 | |
| SCHEMBL613747 | 0.78 | CSNK2A1 (0.69) | CSNK2A1GPR84AHRCMA1F7 | |
| SCHEMBL8957501 | 0.76 | GPR84 (0.46) | CSNK2A1GPR84AHRCMA1F7 | |
| SCHEMBL5236426 | 0.76 | GPR84 (0.64) | CSNK2A1GPR84AHRCMA1F7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111448190-B | Substituted indole compounds | 百时美施贵宝公司 | 2023-09-26 | — | — | CN | disclosed |
| US-11739098-B2 | Substituted indole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-29 | — | — | US | disclosed |
| EP-3710440-B1 | SUBSTITUTED INDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20230098244-A1 | SUBSTITUTED INDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-03-30 | — | — | US | disclosed |
| US-20210253593-A1 | SUBSTITUTED INDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-08-19 | — | — | US | disclosed |
| EP-3710440-A1 | SUBSTITUTED INDOLE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2020-09-23 | — | — | EP | disclosed |
| CN-111448190-A | Substituted indole compounds | 百时美施贵宝公司 | 2020-07-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230098244-A1 | SUBSTITUTED INDOLE COMPOUNDS | TLR7, TLR1, HTR7 | CSNK2A1 2242/4885GPR84 221/4885AHR 30/4885 |
| US-20210253593-A1 | SUBSTITUTED INDOLE COMPOUNDS | TLR7, TLR1, HTR7 | CSNK2A1 2242/4885GPR84 221/4885AHR 30/4885 |
| US-11739098-B2 | Substituted indole compounds | TLR7, TLR1, HTR7 | CSNK2A1 2242/4885GPR84 221/4885AHR 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.